Cargando…

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-wor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salles, Gilles, Schuster, Stephen J., Dreyling, Martin, Fischer, Luca, Kuruvilla, John, Patten, Piers E.M., von Tresckow, Bastian, Smith, Sonali M., Jiménez-Ubieto, Ana, Davis, Keith L., Anjos, Carla, Chu, Jufen, Zhang, Jie, Lobetti Bodoni, Chiara, Thieblemont, Catherine, Fowler, Nathan H., Dickinson, Michael, Martínez-López, Joaquin, Wang, Yucai, Link, Brian K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649992/ https://www.ncbi.nlm.nih.gov/pubmed/35973192 http://dx.doi.org/10.1182/bloodadvances.2022008150

Ejemplares similares

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
por: Salles, Gilles, et al.
Publicado: (2022)

Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022)

Tisagenlecleucel for B-cell cancers
Publicado: (2019)

The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells
por: Townsend, William, et al.
Publicado: (2020)

Tisagenlecleucel: Hypogammaglobulinaemia and pancytopenia: case report
Publicado: (2021)

New Treatment Options in Advanced Stage Follicular Lymphoma
por: Hübel, Kai, et al.
Publicado: (2018)

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma
por: Cuffel, Alexis, et al.
Publicado: (2022)

Tisagenlecleucel: Prolonged neutropenia and thrombocytopenia: case report
Publicado: (2022)

Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma
por: Ghanem, Buthainah
Publicado: (2023)

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, David, et al.
Publicado: (2018)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

A Novel approach using O-CVP to treat paraneoplastic NMO spectrum disorder associated with follicular lymphoma
por: Palmer, David Antony, et al.
Publicado: (2022)

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
por: Porter, D., et al.
Publicado: (2018)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
por: Stein, Andrew M., et al.
Publicado: (2019)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
por: Martín‐Rojas, Reyes Maria, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
por: Yamasaki-Morita, Makiko, et al.
Publicado: (2022)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma
por: Ladetto, Marco, et al.
Publicado: (2021)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay
por: Davis, Lisa, et al.
Publicado: (2020)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
por: Woo, Timothy, et al.
Publicado: (2023)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/tisagenlecleucel: Various toxicities: 2 case reports
Publicado: (2021)

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
por: Kakkassery, Helen, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v50rhgfnvsr4oo6p391qlvndoc